{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:51:24Z","timestamp":1778881884855,"version":"3.51.4"},"publisher-location":"Berlin, Heidelberg","reference-count":50,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642544897","type":"print"},{"value":"9783642544903","type":"electronic"}],"license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-3-642-54490-3_3","type":"book-chapter","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T09:36:51Z","timestamp":1398159411000},"page":"67-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nilotinib"],"prefix":"10.1007","author":[{"given":"Benjamin N.","family":"Ostendorf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,23]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner G-H et al (2011) Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86:533\u2013539","journal-title":"Am J Hematol"},{"key":"3_CR2","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018\u20131029","journal-title":"Lancet Oncol"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041\u20136051","journal-title":"J Clin Oncol"},{"key":"3_CR4","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O\u2019Hare T et al (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108:2332\u20132338","journal-title":"Blood"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","volume":"104","author":"J Cortes","year":"2004","unstructured":"Cortes J, O\u2019Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204\u20132205","journal-title":"Blood"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1200\/JCO.2003.11.143","volume":"21","author":"MWN Deininger","year":"2003","unstructured":"Deininger MWN, O\u2019Brien SG, Ford JM et al (2003) Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21:1637\u20131647","journal-title":"J Clin Oncol"},{"key":"3_CR8","doi-asserted-by":"crossref","first-page":"338S","DOI":"10.1200\/jco.2006.24.18_suppl.6506","volume":"24","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien S et al (2006) Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J Clin Oncol 24:338S\u2013338S","journal-title":"J Clin Oncol"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561\u2013566","journal-title":"Nat Med"},{"key":"3_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.hoc.2011.09.005","volume":"25","author":"T Ernst","year":"2011","unstructured":"Ernst T, La Rosee P, Mueller MC, Hochhaus A (2011) Bcr-Abl mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am 25:997\u20131008","journal-title":"Hematol Oncol Clin North Am"},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2010.110","volume":"24","author":"FJ Giles","year":"2010","unstructured":"Giles FJ, Abruzzese E, Rosti G et al (2010) Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 24:1299\u20131301","journal-title":"Leukemia"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/leu.2011.355","volume":"26","author":"FJ Giles","year":"2012","unstructured":"Giles FJ, Kantarjian HM, le Coutre PD et al (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:959\u2013962","journal-title":"Leukemia"},{"key":"3_CR13","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1200\/jco.2008.26.15_suppl.7017","volume":"26","author":"FJ Giles","year":"2008","unstructured":"Giles FJ, Larson RA, Kantarjian HM (2008) Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib\u2014Giles et al. 26 (15 Supplement): 7017\u2014ASCO Meeting Abstracts. J Clin Oncol 26:7017","journal-title":"J Clin Oncol"},{"key":"3_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J et al (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27:107\u2013112","journal-title":"Leukemia"},{"key":"3_CR15","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","volume":"11","author":"M Golemovic","year":"2005","unstructured":"Golemovic M, Verstovsek S, Giles F et al (2005) AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11:4941\u20134947","journal-title":"Clin Cancer Res"},{"key":"3_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K et al (2001) Clinical resistance to STI-571 cancer therapy caused by Bcr-Abl gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"3_CR17","doi-asserted-by":"publisher","first-page":"E75","DOI":"10.1182\/blood-2010-07-294330","volume":"117","author":"A Haouala","year":"2011","unstructured":"Haouala A, Widmer N, Duchosal MA et al (2011) Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117:E75\u2013E87","journal-title":"Blood"},{"key":"3_CR18","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1182\/blood-2012-04-423418","volume":"121","author":"A Hochhaus","year":"2013","unstructured":"Hochhaus A, Saglio G, Larson RA et al (2013) Nilotinib is associated with a reduced incidence of Bcr-Abl mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 121:3703\u20133708","journal-title":"Blood"},{"key":"3_CR19","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Nazha A et al (2013) Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 121:4867\u20134874","journal-title":"Blood"},{"key":"3_CR20","doi-asserted-by":"crossref","first-page":"302B","DOI":"10.1182\/blood.V106.11.4887.4887","volume":"106","author":"M Kagan","year":"2005","unstructured":"Kagan M, Tran P, Fischer V et al (2005) Safety, pharmacokinetics (PK), metabolism, and mass balance of [C-14]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects. Blood 106:302B\u2013302B","journal-title":"Blood"},{"key":"3_CR21","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542\u20132551","journal-title":"N Engl J Med"},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N et al (2007) Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540\u20133546","journal-title":"Blood"},{"key":"3_CR23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN et al (2011a) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117:1141\u20131145","journal-title":"Blood"},{"key":"3_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G et al (2011b) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841\u2013851","journal-title":"Lancet Oncol"},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M et al (2013) Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27:1316\u20131321","journal-title":"Leukemia"},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP et al (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197\u20132203","journal-title":"Leukemia"},{"key":"3_CR27","doi-asserted-by":"crossref","unstructured":"Larson RA, Hochhaus A, Saglio G et al. (2013) Nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year update. J Clin Oncol (suppl) 31:abstr. 7052","DOI":"10.1200\/jco.2013.31.15_suppl.7052"},{"key":"3_CR28","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P le Coutre","year":"2008","unstructured":"le Coutre P, Ottmann OG, Giles F et al (2008) Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834\u20131839","journal-title":"Blood"},{"key":"3_CR29","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djr292","volume":"103","author":"P le Coutre","year":"2011","unstructured":"le Coutre P, Rea D, Abruzzese E et al (2011) Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 103:1347\u20131348","journal-title":"J Natl Cancer Inst"},{"key":"3_CR30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/leu.2011.323","volume":"26","author":"PD le Coutre","year":"2012","unstructured":"le Coutre PD, Giles FJ, Hochhaus A et al (2012) Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 26:1189\u20131194","journal-title":"Leukemia"},{"key":"3_CR31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/asheducation.V2012.1.122.3798214","volume":"2012","author":"F-X Mahon","year":"2012","unstructured":"Mahon F-X (2012) Is going for cure in chronic myeloid leukemia possible and justifiable? Hematology Am Soc Hematol Educ Program 2012:122\u2013128","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3_CR32","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, Rea D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"3_CR33","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1016\/j.bmcl.2004.09.042","volume":"14","author":"PW Manley","year":"2004","unstructured":"Manley PW, Breitenstein W, Br\u00fcggen J et al (2004) Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDCFR kinases. Bioorg Med Chem Lett 14:5793\u20135797","journal-title":"Bioorg Med Chem Lett"},{"key":"3_CR34","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MWN (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242\u20132249","journal-title":"Blood"},{"key":"3_CR35","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500\u20134505","journal-title":"Cancer Res"},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","volume":"12","author":"A Quint\u00e1s-Cardama","year":"2012","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J (2012) Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 12:337\u2013340","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3_CR37","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","volume":"109","author":"A Ray","year":"2007","unstructured":"Ray A, Cowan-Jacob SW, Manley PW et al (2007) Identification of Bcr-Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 109:5011\u20135015","journal-title":"Blood"},{"key":"3_CR38","first-page":"604","volume":"118","author":"D Rea","year":"2011","unstructured":"Rea D, Rousselot P, Nicolini FE et al (2011) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable Bcr-Abl transcripts: results from the French CML group (FILMC). ASH Annual Meeting Abstracts 118:604","journal-title":"ASH Annual Meeting Abstracts"},{"key":"3_CR39","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23338","volume":"87","author":"S Redaelli","year":"2012","unstructured":"Redaelli S, Mologni L, Rostagno R et al (2012) Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 87:E125\u2013E128","journal-title":"Am J Hematol"},{"key":"3_CR40","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Duernberger G et al (2007) Chemical proteomic profiles of the Bcr-Abl inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets. Blood 110:4055\u20134063","journal-title":"Blood"},{"key":"3_CR41","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515\u2013522","journal-title":"Blood"},{"key":"3_CR42","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"3_CR43","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530\u20133539","journal-title":"Blood"},{"key":"3_CR44","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B et al (2002) Multiple Bcr-Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117\u2013125","journal-title":"Cancer Cell"},{"key":"3_CR45","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928\u20131937","journal-title":"Blood"},{"key":"3_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/clpt.2009.208","volume":"87","author":"C Tanaka","year":"2009","unstructured":"Tanaka C, Yin OQP, Sethuraman V et al (2009) Clinical pharmacokinetics of the Bcr\u2013Abl tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87:197\u2013203","journal-title":"Clin Pharmacol Ther"},{"key":"3_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0091270010367428","volume":"51","author":"C Tanaka","year":"2011","unstructured":"Tanaka C, Yin OQP, Smith T et al (2011) Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 51:75\u201383","journal-title":"J Clin Pharmacol"},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","volume":"108","author":"N von Bubnoff","year":"2006","unstructured":"von Bubnoff N, Manley PW, Mestan J et al (2006) Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108:1328\u20131333","journal-title":"Blood"},{"key":"3_CR48","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J et al (2006) AMN107 (nilotinib): a novel and selective inhibitor of Bcr-Abl. Br J Cancer 94:1765\u20131769","journal-title":"Br J Cancer"},{"key":"3_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"3_CR50","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/0091270009336137","volume":"50","author":"OQP Yin","year":"2010","unstructured":"Yin OQP, Gallagher N, Li A et al (2010) Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 50:188\u2013194","journal-title":"J Clin Pharmacol"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-54490-3_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T23:35:55Z","timestamp":1675985755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-54490-3_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"ISBN":["9783642544897","9783642544903"],"references-count":50,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-54490-3_3","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]},"assertion":[{"value":"23 April 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}